ライフサイエンスコーパス: erectile dysfunction

1 wer administered dosage for the treatment of erectile dysfunction.

2 cular diseases to pulmonary hypertension and erectile dysfunction.

3 lation between cigarette smoking and risk of erectile dysfunction.

4 age, respectively, relative to those without erectile dysfunction.

5 PDE V inhibitor that is used clinically for erectile dysfunction.

6 ment or prophylaxis exists for posttreatment erectile dysfunction.

7 1a (ABT-724) for the potential treatment of erectile dysfunction.

8 potential risk factor for the development of erectile dysfunction.

9 clinical endpoints: late rectal bleeding and erectile dysfunction.

10 onent of therapy for men with depression and erectile dysfunction.

11 low quality of life contributes to or causes erectile dysfunction.

12 static hyperplasia are definitely related to erectile dysfunction.

13 This effect has led to its use for treating erectile dysfunction.

14 escribing an association between smoking and erectile dysfunction.

15 and it is this that contributes to or causes erectile dysfunction.

16 unction, and loss of the BK channel leads to erectile dysfunction.

17 836 had previously smoked, and 203 reported erectile dysfunction.

18 ion-making when confronted by a patient with erectile dysfunction.

19 and is effective in patients suffering from erectile dysfunction.

20 ABT-724 could be useful for the treatment of erectile dysfunction.

21 also associated with increased prevalence of erectile dysfunction.

22 potential new strategy for the treatment of erectile dysfunction.

23 egies may exist for gene-based treatments of erectile dysfunction.

24 utility of gene therapy for the treatment of erectile dysfunction.

25 lication of gene therapy to the treatment of erectile dysfunction.

26 in and Germany have suggested lower rates of erectile dysfunction.

27 Rho kinase inhibitor suitable for therapy of erectile dysfunction.

28 be possible to identify patients at risk of erectile dysfunction.

29 ential alternate avenue for the treatment of erectile dysfunction.

30 ations include penile deformity and possible erectile dysfunction.

31 e-dependent smooth muscle disorders, such as erectile dysfunction.

32 raction, such as hypertension, glaucoma, and erectile dysfunction.

33 Men 60 years of age with erectile dysfunction.

34 ibitor, is an orally effective treatment for erectile dysfunction.

35 effective and widely prescribed therapy for erectile dysfunction.

36 herapeutic intervention for the treatment of erectile dysfunction.

37 ctive, well-tolerated treatment for men with erectile dysfunction.

38 ated with devastating complications, notably erectile dysfunction.

39 the stroke and therefore had stroke-related erectile dysfunction.

40 One patient in each group reported erectile dysfunction.

41 pisodic dry eyes and mouth, hot flashes, and erectile dysfunction.

42 ion, implying unique approaches for treating erectile dysfunction.

43 ccess of PDE5 inhibitors in the treatment of erectile dysfunction.

44 ng would each result in 1 additional case of erectile dysfunction.

45 rted use of medications or other devices for erectile dysfunction.

46 emain a viable tertiary treatment option for erectile dysfunction.

47 such as asthma, cardiovascular diseases, and erectile dysfunction.

48 ibitors in patients with coexisting LUTS and erectile dysfunction.

49 denafil, etc.) are first-line treatments for erectile dysfunction.

50 atic hypotension, sweating abnormalities, or erectile dysfunction.

51 -eye movement sleep behaviour disorder), and erectile dysfunction.

52 nitourinary complications, incontinence, and erectile dysfunction.

53 ssociation with penile fibrosis and eventual erectile dysfunction.

54 l testing in and pharmacologic management of erectile dysfunction.

55 diated erectile tissue damage and subsequent erectile dysfunction.

56 , 2.04-2.46), hypotension (3.23, 1.85-5.52), erectile dysfunction (1.30, 1.11-1.51), urinary dysfunct

57 ir forties had the greatest relative odds of erectile dysfunction, 2.74 (95% confidence interval (CI)

58 9 vs 12.2 per 100 person-years; P = .02) and erectile dysfunction (26.8 vs 19.2 per 100 person-years;

59 d ratio 1.03 [95% CI 0.88-1.21]; p=0.72) and erectile dysfunction (272 [1.86% per annum] vs 302 [2.14

60 32%; P: = .010) but less frequently reported erectile dysfunction (56% v 72%; P: = .048).

61 ations: hot flashes (70%), nausea (34%), and erectile dysfunction (81%).

62 e efforts being made to reduce posttreatment erectile dysfunction, a major morbidity of these therapi

63 3) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100

64 tudy entry, 2420 men (57%) reported incident erectile dysfunction after 5 years.

65 morbidities may have a significant impact on erectile dysfunction after CaP treatment.

66 d tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are

67 Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, bu

68 Erectile dysfunction after radical therapy for CaP may b

69 ked at some time had a greater likelihood of erectile dysfunction (age-adjusted odds ratio = 1.42, 95

70 phosphodiesterase 5 inhibitor used to treat erectile dysfunction, ameliorates high glucose stimulati

71 iation between cigarette smoking and risk of erectile dysfunction among 7,684 Chinese men aged 35-74

72 The 5-year likelihood of posttreatment erectile dysfunction among patients who were initially p

73 as to quantify the prevalence of concomitant erectile dysfunction and active depression among patient

74 Erectile dysfunction and cardiovascular disease share th

75 e the foundation for the strong link between erectile dysfunction and cardiovascular disease.

76 els were used to evaluate the association of erectile dysfunction and cardiovascular disease.

77 etermine associations between stroke-related erectile dysfunction and cerebral ischaemic lesion sites

78 Erectile dysfunction and depression are highly associate

79 Concomitant erectile dysfunction and depression represent a signific

80 .5, 16.7), and the prevalence of concomitant erectile dysfunction and depression was 5.1% (95% CI: 2.

81 l treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life.

82 A/Rho-kinase contributes to diabetes-related erectile dysfunction and down-regulation of eNOS in the

83 ng evidence for an association between LUTS, erectile dysfunction and ejaculatory dysfunction.

84 orts the link between metabolic syndrome and erectile dysfunction and highlights metabolic syndrome a

85 dities associated with prostatectomy, namely erectile dysfunction and incontinence.

86 s showed associations between stroke-related erectile dysfunction and lesion sites in the right occip

87 Erectile dysfunction and low testosterone levels frequen

88 o in improving erectile function in men with erectile dysfunction and low testosterone levels.

89 effects of sildenafil treatment in men with erectile dysfunction and mild-to-moderate comorbid depre

90 odiesterase that is used clinically to treat erectile dysfunction and pulmonary arterial hypertension

91 tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.

92 inary incontinence, anastomotic contracture, erectile dysfunction and rectourethral fistula (RUF) for

93 ce of underlying cardiac disease in men with erectile dysfunction and reports indicating serious card

94 prostatectomy is associated with significant erectile dysfunction and some decline in urinary functio

95 afety and efficacy of vardenafil in men with erectile dysfunction and untreated mild depression.

96 tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression

97 DE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindicat

98 ab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a haem

99 rapeutic target for the treatment of asthma, erectile dysfunction, and atherosclerosis.

100 and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are g

101 isorders including congestive heart failure, erectile dysfunction, and inflammation.

102 failure like infertility, low testosterone, erectile dysfunction, and low bone mineral density.

103 Depressed men commonly have erectile dysfunction, and men with erectile dysfunction

104 apter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD.

105 Proximal myopathy, erectile dysfunction, and myelosuppression precluded the

106 degree of curvature, the type of deformity, erectile dysfunction, and penile length are all characte

107 er symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass.

108 rome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

109 Bowel continence, erectile dysfunction, and social life disturbance were n

110 Erectile dysfunction appears to be one of the earliest s

111 ival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those s

112 only have erectile dysfunction, and men with erectile dysfunction are frequently depressed.

113 ng evidence that endothelial dysfunction and erectile dysfunction are linked.

114 risk factors for cardiovascular disease and erectile dysfunction are similar.

115 phosphodiesterase-5 inhibitor treatment for erectile dysfunction associated with antidepressant ther

116 going prostatectomy were more likely to have erectile dysfunction at 2 years (odds ratio, 3.46; 95% C

117 was 0.015 per person-year among men without erectile dysfunction at study entry and was 0.024 per pe

118 Among the 4247 men without erectile dysfunction at study entry, 2420 men (57%) repo

119 at study entry; of these men, 3816 (47%) had erectile dysfunction at study entry.

120 y and was 0.024 per person-year for men with erectile dysfunction at study entry.

121 Men with erectile dysfunction before 1986 were 3.8 times more lik

122 0.008) for participants with first onset of erectile dysfunction (before 1986) at 60 or more, 50-59,

123 very 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003.

124 such as sildenafil are widely used to treat erectile dysfunction, but growing evidence supports impo

125 argets that are amenable to gene therapy for erectile dysfunction, but rather in the safety, specific

126 nhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascula

127 Erectile dysfunction can be devastating for men and for

128 ole of endothelium in the pathophysiology of erectile dysfunction, cardiovascular disease, and the me

129 Other comorbidities including erectile dysfunction, cardiovascular diseases should als

130 association is causal, an estimated 22.7% of erectile dysfunction cases (11.8 million cases) among Ch

131 antiandrogens and managing treatment-induced erectile dysfunction continue to benefit patients with p

132 of energy, depressed mood, decreased libido, erectile dysfunction, decreased muscle mass and strength

133 Erectile dysfunction, defined as the consistent inabilit

134 In patients with refractory erectile dysfunction, dexterous and motivated patients r

135 he International Index of Erectile Function (Erectile Dysfunction Domain) score >/= 4 points in >/= 5

136 tes, 477 (21%) used cannabis, 460 (21%) used erectile dysfunction drugs, 453 (20%) used cocaine, 280

137 The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PD

138 D) risk factors measured in mid-life predict erectile dysfunction (ED) 25 years later.

139 he internal pudendal arteries among men with erectile dysfunction (ED) and a suboptimal response to p

140 to determine whether patients with vascular erectile dysfunction (ED) and no other clinical cardiova

141 Chronic heart failure (HF) and erectile dysfunction (ED) are 2 highly prevalent disorde

142 Erectile dysfunction (ED) carries an independent risk fo

143 Pharmacologic treatments for erectile dysfunction (ED) have gained popularity among m

144 Erectile dysfunction (ED) is a highly prevalent and ofte

145 Erectile dysfunction (ED) is common among men with CAD.

146 Erectile dysfunction (ED) is estimated to affect more th

147 Erectile dysfunction (ED) is recognized as a major publi

148 The predominant etiology for erectile dysfunction (ED) is vascular, but limited data

149 This study was designed to determine whether erectile dysfunction (ED) predicts cardiovascular diseas

150 hough there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (C

151 terase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval.

152 accounts significantly for the prevalence of erectile dysfunction (ED).

153 degeneration of the cavernous nerve (CN) and erectile dysfunction (ED).

154 osis, which is relevant to the occurrence of erectile dysfunction (ED).

155 less legs syndrome (RLS) was associated with erectile dysfunction (ED).

156 ers, and both share common risk factors with erectile dysfunction (ED).

157 function tenderness, frequent urination, and erectile dysfunction [ED]) and measures of physical and

158 t and demand for clinical services regarding erectile dysfunction, epidemiologic data on sexual dysfu

159 Men (N=152, mean age=56 years) with erectile dysfunction for > or =6 months (mean=5.7 years)

160 tion therapy for ischemic and any stroke and erectile dysfunction for any stroke.

161 llel-group, double-blind study, 280 men with erectile dysfunction for at least 6 months and untreated

162 he technology used intraoperatively, induces erectile dysfunction for most men who undergo the proced

163 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes.

164 surgery), antiandrogen therapy management of erectile dysfunction, funding and legislation for resear

165 is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon

166 logical conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidn

167 treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to de

168 levels such as hot flushes, lack of libido, erectile dysfunction, gynecomastia and bone mineral dens

169 Erectile dysfunction has a negative impact on health-rel

170 with potential utility for the treatment of erectile dysfunction has been discovered, guided by the

171 Radiological imaging in the field of erectile dysfunction has diminished in importance over t

172 tive inhibitor of PDE5 used for treatment of erectile dysfunction, has been found to cause relaxation

173 ulatory relationships between depression and erectile dysfunction have been poorly characterized, a 1

174 s of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional canc

175 ) increases cGMP and is used widely to treat erectile dysfunction; however, its role in the heart and

176 l morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy

177 understanding of the cause and management of erectile dysfunction in CaP survivors.

178 synthase (eNOS) function is associated with erectile dysfunction in diabetes mellitus, but the exact

179 ldenafil is safe and efficacious in treating erectile dysfunction in diabetic patients.

180 etrospective questionnaire with questions on erectile dysfunction in different time periods.

181 il citrate is effective for the treatment of erectile dysfunction in men taking concomitant serotonin

182 n effective and well-tolerated treatment for erectile dysfunction in men with diabetes.

183 Sildenafil is efficacious for erectile dysfunction in men with mild-to-moderate depres

184 Common disturbances include erectile dysfunction in men, menstrual abnormalities in

185 a) is the most widely used drug for treating erectile dysfunction in men.

186 Sildenafil significantly improved erectile dysfunction in patients taking concomitant sero

187 Although no standard management of erectile dysfunction in prostate cancer (CaP) survivors

188 Although many studies have provided data on erectile dysfunction in specific settings, few studies h

189 excluded, the age-standardized prevalence of erectile dysfunction in the previous 3 months was 33%.

190 ot support daily use of tadalafil to prevent erectile dysfunction in these patients.

191 The prevalence of moderate or complete erectile dysfunction in this sample was 36.4% (95% confi

192 of poor morning erection, low sexual desire, erectile dysfunction, inability to perform vigorous acti

193 or on the individual preferences of men with erectile dysfunction, including ease of use, cost of med

194 Risks of erectile dysfunction, incontinence, and disease recurren

195 mplants for genitourinary reconstruction for erectile dysfunction, incontinence, and orchiectomy have

196 In men with erectile dysfunction, intracavernosal injection of alpro

197 Erectile dysfunction is a common medical problem affecti

198 Erectile dysfunction is a common problem, affecting more

199 Erectile dysfunction is a harbinger of cardiovascular cl

200 Erectile dysfunction is a neurovascular phenomenon that

201 Erectile dysfunction is a worldwide health issue that af

202 Erectile dysfunction is also strongly associated with a

203 Improvement of erectile dysfunction is associated with marked improveme

204 Erectile dysfunction is common after radical prostatecto

205 Erectile dysfunction is common among individuals with Pa

206 Erectile dysfunction is common in men with diabetes.

207 , gene-based strategies for the treatment of erectile dysfunction is consistent with the multifactori

208 the influence of CP/CPPS on the incidence of erectile dysfunction is scant.

209 y result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE

210 ibitors such as 2a for potential use in male erectile dysfunction (MED).

211 mpounds demonstrated in vivo efficacy in dog erectile dysfunction models and are orally bioavailable.

212 applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addit

213 activity was associated with lower risk for erectile dysfunction (multivariable relative risk, 0.7 [

214 Erectile dysfunction occurred frequently after all treat

215 ere not associated with moderate or complete erectile dysfunction (odds ratio = 1.3, 95% CI: 0.5, 3.1

216 rog in 23, 20, 38 and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psycho

217 sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, and mixed

218 stitutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psycho

219 tain patients who already have some baseline erectile dysfunction or are not candidates for nerve-spa

220 (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, th

221 to enhance sex (p=0.0006), use of drugs for erectile dysfunction (p<0.0001), and 100% condom use (p<

222 lation between cigarette smoking and risk of erectile dysfunction (p(trend) = 0.005).

223 lockbuster status in the treatment of penile erectile dysfunction (PED).

224 disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontitis, inflammatory bowel

225 Erectile dysfunction rates are universally high after wh

226 (12-26 weeks) identified a group of men with erectile dysfunction receiving 5 to 200 mg/day of silden

227 Patients with erectile dysfunction receiving sildenafil and concomitan

228 f this work is to review the fundamentals of erectile dysfunction relevant to the postprostatectomy p

229 gression analysis showed that stroke-related erectile dysfunction remained associated with lesions of

230 ased lesion analysis, the difference between erectile dysfunction scores before and after stroke was

231 as brain volumes and the difference between erectile dysfunction scores before and after stroke.

232 In 32 patients (61.5%) erectile dysfunction scores declined after the stroke an

233 Deterioration of erectile dysfunction scores was not associated with pati

234 Erectile dysfunction should be included as an outcome in

235 Erectile dysfunction should prompt investigation and int

236 prespecified AEs of interest-muscle-related, erectile dysfunction, sleep disturbance, and cognitive i

237 are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complicat

238 in the advent of PDE5 inhibitors that treat erectile dysfunction, such as Viagra, Levitra, and Ciali

239 ata linking lower urinary tract symptoms and erectile dysfunction suggest that lower urinary tract sy

240 duced over 30 years ago for the treatment of erectile dysfunction, technological innovations have con

241 vent of oral medication for the treatment of erectile dysfunction the disease has garnered increasing

242 For men with either incident or prevalent erectile dysfunction, the hazard ratio was 1.45 (95% CI,

243 oral erectogenic agents for the treatment of erectile dysfunction, there will always be patients who

244 nt, to assess and treat side-effects such as erectile dysfunction, to switch to less costly generic a

245 Conservative criteria were used to classify erectile dysfunction treatment response and nonresponse.

246 Sildenafil was strongly associated with erectile dysfunction treatment response.

247 Erectile dysfunction treatment should be considered a co

248 less adverse effects in humans when used for erectile dysfunction treatment.

249 nary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]).

250 tonomic features (constipation, hypotension, erectile dysfunction, urinary dysfunction, and dizziness

251 The results were sensitive to variation of erectile dysfunction utilities, but cost per QALY gained

252 T vs no ADT and 1.35 (95% CI, 1.18-1.53) for erectile dysfunction vs no dysfunction.

253 and hypercholesterolemia, the odds ratio of erectile dysfunction was 1.41 (95% confidence interval (

254 ire; during the fourth biennial examination, erectile dysfunction was assessed with the Brief Male Se

255 After adjustment, incident erectile dysfunction was associated with a hazard ratio

256 rge cohort of men, the authors observed that erectile dysfunction was associated with a higher risk o

257 this question, the authors examined whether erectile dysfunction was associated with Parkinson's dis

258 The association between smoking and erectile dysfunction was evaluated in a cohort of 2,115

259 ts due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride

260 Multivariate-adjusted odds ratios of erectile dysfunction were 1.27 (95% CI: 0.91, 1.77), 1.4

261 Cigarette smoking and erectile dysfunction were assessed by questionnaire.

262 estyle factors most strongly associated with erectile dysfunction were physical activity and leanness

263 ica albuginea, is reserved for patients with erectile dysfunction who have not responded to medical t

264 nt of non-life threatening disorders such as erectile dysfunction, will be outlined.